H1N1 Vaccine Market Growth Outlook Through 2024-2033

Overview and Scope
H1N1 vaccines are administered to people six months of age and older to immunize them against influenza diseases brought on by the H1N1 2009 virus. These are used to prevent humans from Influenza virus infection by injecting a small dose of the virus inside the body to build immunity against the virus.

Sizing and Forecast
The h1n1 vaccine market size has grown strongly in recent years. It will grow from $3.16 billion in 2023 to $3.37 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to previous influenza outbreaks, global health security concerns, vaccine development and approval processes, global vaccination campaigns, public health education initiatives, government funding and subsidies, pharmaceutical industry agility..

The h1n1 vaccine market size is expected to see strong growth in the next few years. It will grow to $4.46 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to research on broad-spectrum vaccines, global vaccine equity initiatives, public health resilience building, global health governance strengthening, integration of h1n1 vaccination with routine immunization.. Major trends in the forecast period include global pandemic preparedness, influenza vaccination programs, vaccine development advances, cross-protection research, global health initiatives, technological improvements in vaccine manufacturing, production capacity expansion, data monitoring and surveillance..

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report

Segmentation & Regional Insights
The h1n1 vaccine market covered in this report is segmented –

1) By Product Type: Inactivated Vaccine, Live Attenuated Vaccine
2) By Route Of Administration: Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination
3) By End Users: Hospitals, Clinics, Research and Diagnostic Laboratories, Other End Users

North America was the largest region in the H1N1 vaccine market in 2023. The regions covered in the h1n1 vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7881&type=smp

Major Driver Impacting Market Growth
The increase in expenditure for research and development activities in the field of immunology and vaccine is expected to propel the growth of the H1N1 vaccine market going forward. Immunology and vaccines are used to prevent infections and help in producing antibodies to fight infections. Immunology is a crucial area of research in the medical and biological sciences that focuses on understanding the immune system. The H1N1 vaccine is a preparation used to boost antibody production, which provides immunity against a variety of diseases. For instance, according to an article by the kENUP Foundation, a Europe-based non-profit supporting research-based innovation in health industries, in January 2021, governments spent at least $94.11 billion (€93 billion) on the development of vaccines and treatments since the start of the pandemic worldwide. The public sector committed 95% of the total spending, or $87.54 billion (€86.5 billion), in just 11 months to the development of vaccinations. Therefore, increasing expenditure for research and development activities in the field of immunology and vaccines is driving the growth of the H1N1 vaccine market.

Key Industry Players
Major companies operating in the h1n1 vaccine market report are Sanofi SA, Novartis AG, GlaxoSmithKline plc, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Baxter Laboratories Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Abbott Laboratories, Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Takeda Pharmaceutical Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Daiichi Sankyo Chemical Pharma Co. Ltd., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., GeoVax Labs Inc.

The h1n1 vaccine market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model